InnoUp Farma, backed by Sodena, Successfully Completes Phase 1 Trial of INP20, Its Innovative Oral Immunotherapy for Peanut Allergy
Biotechnology company InnoUp Farma has successfully completed a Phase 1 clinical trial of INP20, an oral immunotherapy candidate designed to treat peanut allergies. The study, which enrolled 52 participants aged 12 to 65, showed a significant 8.9-fold increase in the biomarker immunoglobulin G4 (IgG4), which is linked to immune tolerance. The company, supported by the Navarra-based agency Sodena, is now preparing for Phase 2 development.
How INP20 differs from current allergy treatments
Unlike existing therapies that work to desensitize patients to specific allergens, INP20 targets the root cause of food allergies. According to InnoUp Farma, the treatment is designed to replicate biological signals from the gut microbiota that naturally promote immune tolerance. This approach seeks to modulate the immune response in a more durable way than current methods that focus primarily on symptom reduction.
The Phase 1 trial results showed that the immune response in participants continued to rise even two weeks after the final dose of the 14-day treatment regimen.
What happens during the next phase of development
InnoUp Farma is moving toward a Phase 2 trial following the completion of the initial safety and activity testing. While the company prepares for this next stage, the full results from the Phase 1 trial are undergoing peer review for potential publication in the journal Nature Medicine. A preprint version of the study is currently available to the scientific community through open access.
Samantha Carter notes that the move from symptom management to targeting the underlying mechanisms of immune tolerance represents a potential shift in how clinicians approach food allergies. If Phase 2 trials confirm these early findings, the therapy could offer a more sustainable path for patients who currently rely on strict avoidance or temporary desensitization protocols.
Frequently Asked Questions
Who participated in the Phase 1 trial?
The trial included 52 patients between the ages of 12 and 65 who received a once-daily dose of INP20 for 14 days.
What is the significance of the IgG4 increase?
Immunoglobulin G4 (IgG4) is a biomarker associated with immune tolerance; participants in the study recorded an 8.9-fold increase over baseline levels.
Is the treatment available for public use?
No, the treatment is currently in the clinical development stage and is not yet available for public use.
How might a treatment that targets the root cause of allergies change your daily approach to food safety?